Cyanotech Posts $7.2M Loss Amidst Debt Management

TL;DR

**CYAND is bleeding cash with a $7.2M loss; steer clear until they show a path to profitability.**

AI Summary

CYANOTECH CORP (CYAND) reported a net loss of $7,232,217 for the quarter ended June 30, 2025, a significant increase from the $7,199,908 net loss reported in the prior fiscal year. The company's common stock outstanding remained at 10,000,000 shares, with an authorized share capital of 50,000,000 shares. Key business changes include the continued reliance on a revolving credit facility with First Foundation Bank, which had a balance of $203,000 as of June 30, 2025, and a related party revolving credit facility with a balance of $0. The company also maintains a term loan agreement maturing on August 14, 2032, and an unsecured subordinated loan from Skywords, initiated on April 30, 2019. Risks include customer concentration, as evidenced by the disclosure of sales revenue net from customer concentration risk. The strategic outlook appears focused on managing existing debt obligations and maintaining operations with current financing structures.

Why It Matters

This filing reveals CYANOTECH CORP's continued financial struggles, with a net loss exceeding $7.2 million, which directly impacts investor confidence and potential for future growth. The reliance on revolving credit facilities, including a related party loan, signals ongoing liquidity challenges, potentially affecting employees through job security and customers through product availability or pricing. In a competitive market for medicinal chemicals and botanical products, these financial pressures could hinder innovation and market share, making it difficult for CYANOTECH to compete with more financially stable rivals.

Risk Assessment

Risk Level: high — The company reported a net loss of $7,232,217 for the quarter, indicating significant financial distress. Furthermore, the disclosure of 'Customer Concentration Risk' suggests vulnerability to the loss of a major client, which could severely impact its already negative revenue stream. The ongoing reliance on revolving credit facilities and subordinated loans also points to persistent liquidity issues.

Analyst Insight

Investors should exercise extreme caution and consider divesting from CYAND given the substantial net loss and ongoing financial instability. New investors should avoid this stock until there is clear evidence of a turnaround strategy and sustained profitability.

Key Numbers

• $7.23M — Net Loss (Increased from $7.19M in the prior year, indicating worsening financial performance.)
• 10M — Common Stock Shares Outstanding (Remained constant, suggesting no dilution or buybacks in the quarter.)
• $203K — First Foundation Bank Revolving Credit Facility Balance (Indicates ongoing reliance on external financing for operations.)
• $0 — Related Party Revolving Credit Facility Balance (Suggests no current draw on this facility as of June 30, 2025.)
• 2032 — Term Loan Maturity Year (Provides a long-term debt obligation for the company.)

Key Players & Entities

• CYANOTECH CORP (company) — filer of the 10-Q
• First Foundation Bank (company) — provider of revolving credit facility
• Skywords (company) — provider of unsecured subordinated loan
• $7,232,217 (dollar_amount) — net loss for the quarter ended June 30, 2025
• $7,199,908 (dollar_amount) — net loss for the prior fiscal year
• 10,000,000 (dollar_amount) — common stock shares outstanding
• 50,000,000 (dollar_amount) — authorized common stock shares
• $203,000 (dollar_amount) — balance on First Foundation Bank revolving credit facility as of June 30, 2025
• August 14, 2032 (date) — maturity date of term loan agreement
• April 30, 2019 (date) — initiation date of unsecured subordinated loan from Skywords

FAQ

Risk Factors

• Customer Concentration Risk [high — financial]: The company explicitly discloses sales revenue net from customer concentration risk, indicating a significant reliance on a limited number of customers. This concentration exposes the company to potential revenue volatility if key customers reduce their purchasing or terminate their relationships.
• Reliance on Revolving Credit Facility [medium — financial]: Cyanotech Corp. maintains a revolving credit facility with First Foundation Bank, with a balance of $203,000 as of June 30, 2025. This ongoing reliance on external financing suggests potential liquidity constraints and dependence on lender relationships for operational continuity.
• Significant Net Loss [high — financial]: The company reported a net loss of $7,232,217 for the quarter ended June 30, 2025, an increase from $7,199,908 in the prior year. This widening loss indicates deteriorating profitability and raises concerns about the company's ability to achieve sustainable financial health.
• Long-Term Debt Obligations [medium — financial]: Cyanotech has a term loan agreement maturing on August 14, 2032, and an unsecured subordinated loan from Skywords initiated on April 30, 2019. These long-term obligations represent significant future financial commitments that require careful management.

Industry Context

Cyanotech Corp. operates within the medicinal chemicals and botanical products sector, focusing on microalgae-based nutritional products. This industry is characterized by growing consumer demand for health and wellness products, but also faces challenges related to scientific validation, regulatory hurdles, and competition from both established players and emerging companies in the nutraceutical space.

Regulatory Implications

As a producer of health-related products, Cyanotech is subject to regulations from bodies like the FDA concerning product safety, labeling, and manufacturing practices. Compliance with these regulations is critical to maintaining market access and consumer trust. Any changes in regulatory requirements or enforcement could impact product development, marketing, and sales.

What Investors Should Do

1. Monitor revenue trends and customer concentration disclosures closely.
2. Evaluate the sustainability of current financing structures.
3. Scrutinize any future disclosures regarding operational improvements or cost-saving measures.

Key Dates

• 2025-06-30: Quarter End Date — Represents the period for which the financial results are reported, showing a net loss of $7,232,217.
• 2025-08-06: Filing Date of 10-Q — Indicates the official release of the company's quarterly financial performance and disclosures.
• 2032-08-14: Term Loan Maturity Date — Marks the final repayment date for a significant long-term debt obligation.
• 2019-04-30: Initiation of Unsecured Subordinated Loan from Skywords — Marks the beginning of a long-term debt obligation that impacts the company's capital structure.

Glossary

Revolving Credit Facility

A type of credit line that allows a company to borrow, repay, and re-borrow funds up to a certain limit over a specified period. (Cyanotech relies on a revolving credit facility with First Foundation Bank, indicating ongoing need for short-term financing for operations.)

Term Loan Agreement

A loan from a bank or other lender for a specific amount that has a specified repayment schedule and a fixed or floating interest rate. (Cyanotech has a term loan maturing in 2032, representing a significant long-term financial commitment.)

Unsecured Subordinated Loan

A loan that is not backed by collateral and ranks below other debts in the event of bankruptcy or liquidation. (The company has an unsecured subordinated loan from Skywords, which has specific terms and repayment obligations.)

Customer Concentration Risk

A risk that arises when a company derives a significant portion of its revenue from a small number of customers. (Cyanotech explicitly mentions this risk, highlighting potential revenue instability due to reliance on a few key clients.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Cyanotech reported a net loss of $7,232,217 for the quarter, indicating that expenses outpaced revenues.)

Year-Over-Year Comparison

The net loss for the quarter ended June 30, 2025, increased to $7,232,217 from $7,199,908 in the prior fiscal year's comparable quarter, indicating a slight deterioration in financial performance. The number of common shares outstanding remained constant at 10,000,000, suggesting no significant equity issuance or buybacks. The company continues to utilize its revolving credit facility, with a balance of $203,000 as of June 30, 2025, similar to its ongoing reliance on financing.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding CYANOTECH CORP (CYAND).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR